化疗-免疫治疗对转移性肺腺癌患者TTF-1生物标志物阴性预后的影响:一项回顾性队列研究

IF 3.5 2区 医学 Q2 ONCOLOGY
Translational lung cancer research Pub Date : 2025-07-31 Epub Date: 2025-07-18 DOI:10.21037/tlcr-2025-65
Luis Posado-Domínguez, Alejandro Olivares-Hernández, Daniel Morchón-Araujo, Luis Figuero-Perez, Lorena Bellido-Hernández, Laura Corvo-Felix, Jonnathan Roldan-Ruiz, Iñigo San Miguel, Emilio Fonseca-Sanchez, Edel Del Barco-Morillo
{"title":"化疗-免疫治疗对转移性肺腺癌患者TTF-1生物标志物阴性预后的影响:一项回顾性队列研究","authors":"Luis Posado-Domínguez, Alejandro Olivares-Hernández, Daniel Morchón-Araujo, Luis Figuero-Perez, Lorena Bellido-Hernández, Laura Corvo-Felix, Jonnathan Roldan-Ruiz, Iñigo San Miguel, Emilio Fonseca-Sanchez, Edel Del Barco-Morillo","doi":"10.21037/tlcr-2025-65","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The prognostic significance of TTF-1 expression in advanced lung adenocarcinoma may be an important factor in optimizing treatment strategies. This study aimed to evaluate the impact of TTF-1 negativity on overall survival (OS) and progression-free survival (PFS) in stage IV lung adenocarcinoma patients with low PD-L1 expression treated with platinum-pemetrexed-pembrolizumab.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 155 patients with stage IV lung adenocarcinoma and PD-L1 expression <50%. We stratified patients according to TTF-1 expression. The primary survival analysis focused on 64 patients who received first-line platinum-pemetrexed chemotherapy in combination with pembrolizumab. We evaluated OS and PFS using Kaplan-Meier curves and multivariate Cox regression.</p><p><strong>Results: </strong>Among patients treated with platinum-pemetrexed-pembrolizumab, TTF-1-negative patients showed significantly shorter OS and numerically shorter PFS compared to TTF-1-positive patients. Median OS was 13 months for TTF-1-negative patients and 21 months for TTF-1-positive patients (P=0.01). Median PFS was 10 <i>vs.</i> 13 months, respectively (P=0.11). In the overall cohort, TTF-1 negativity was independently associated with a 2.3-fold increased risk of mortality (hazard ratio =2.288, 95% confidence interval: 1.073-4.879, P=0.03).</p><p><strong>Conclusions: </strong>TTF-1 negativity is an independent adverse prognostic factor in patients with stage IV lung adenocarcinoma and low PD-L1 expression. The observed differences in survival suggest that platinum-pemetrexed-pembrolizumab may be less effective for TTF-1-negative patients, and that alternative strategies should be explored in this high-risk subgroup.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 7","pages":"2494-2508"},"PeriodicalIF":3.5000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12337030/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prognostic impact of negative TTF-1 biomarker in metastatic lung adenocarcinoma treated with chemo-immunotherapy: a retrospective cohort study.\",\"authors\":\"Luis Posado-Domínguez, Alejandro Olivares-Hernández, Daniel Morchón-Araujo, Luis Figuero-Perez, Lorena Bellido-Hernández, Laura Corvo-Felix, Jonnathan Roldan-Ruiz, Iñigo San Miguel, Emilio Fonseca-Sanchez, Edel Del Barco-Morillo\",\"doi\":\"10.21037/tlcr-2025-65\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The prognostic significance of TTF-1 expression in advanced lung adenocarcinoma may be an important factor in optimizing treatment strategies. This study aimed to evaluate the impact of TTF-1 negativity on overall survival (OS) and progression-free survival (PFS) in stage IV lung adenocarcinoma patients with low PD-L1 expression treated with platinum-pemetrexed-pembrolizumab.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 155 patients with stage IV lung adenocarcinoma and PD-L1 expression <50%. We stratified patients according to TTF-1 expression. The primary survival analysis focused on 64 patients who received first-line platinum-pemetrexed chemotherapy in combination with pembrolizumab. We evaluated OS and PFS using Kaplan-Meier curves and multivariate Cox regression.</p><p><strong>Results: </strong>Among patients treated with platinum-pemetrexed-pembrolizumab, TTF-1-negative patients showed significantly shorter OS and numerically shorter PFS compared to TTF-1-positive patients. Median OS was 13 months for TTF-1-negative patients and 21 months for TTF-1-positive patients (P=0.01). Median PFS was 10 <i>vs.</i> 13 months, respectively (P=0.11). In the overall cohort, TTF-1 negativity was independently associated with a 2.3-fold increased risk of mortality (hazard ratio =2.288, 95% confidence interval: 1.073-4.879, P=0.03).</p><p><strong>Conclusions: </strong>TTF-1 negativity is an independent adverse prognostic factor in patients with stage IV lung adenocarcinoma and low PD-L1 expression. The observed differences in survival suggest that platinum-pemetrexed-pembrolizumab may be less effective for TTF-1-negative patients, and that alternative strategies should be explored in this high-risk subgroup.</p>\",\"PeriodicalId\":23271,\"journal\":{\"name\":\"Translational lung cancer research\",\"volume\":\"14 7\",\"pages\":\"2494-2508\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12337030/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational lung cancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21037/tlcr-2025-65\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational lung cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tlcr-2025-65","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/18 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:TTF-1表达在晚期肺腺癌中的预后意义可能是优化治疗策略的重要因素。本研究旨在评估TTF-1阴性对低PD-L1表达的IV期肺腺癌患者铂-培美曲塞-派姆单抗治疗的总生存期(OS)和无进展生存期(PFS)的影响。方法:我们对155例IV期肺腺癌患者的PD-L1表达进行了回顾性分析。结果:在铂-培美曲塞-派姆单抗治疗的患者中,与ttf -1阳性患者相比,ttf -1阴性患者的OS和PFS显著缩短。ttf -1阴性患者的中位OS为13个月,ttf -1阳性患者的中位OS为21个月(P=0.01)。中位PFS分别为10个月和13个月(P=0.11)。在整个队列中,TTF-1阴性与死亡风险增加2.3倍独立相关(风险比=2.288,95%可信区间:1.073-4.879,P=0.03)。结论:TTF-1阴性是PD-L1低表达的IV期肺腺癌患者的独立不良预后因素。观察到的生存差异表明,铂-培美曲塞-派姆单抗对ttf -1阴性患者可能效果较差,应该在这一高危亚组中探索替代策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Prognostic impact of negative TTF-1 biomarker in metastatic lung adenocarcinoma treated with chemo-immunotherapy: a retrospective cohort study.

Background: The prognostic significance of TTF-1 expression in advanced lung adenocarcinoma may be an important factor in optimizing treatment strategies. This study aimed to evaluate the impact of TTF-1 negativity on overall survival (OS) and progression-free survival (PFS) in stage IV lung adenocarcinoma patients with low PD-L1 expression treated with platinum-pemetrexed-pembrolizumab.

Methods: We conducted a retrospective analysis of 155 patients with stage IV lung adenocarcinoma and PD-L1 expression <50%. We stratified patients according to TTF-1 expression. The primary survival analysis focused on 64 patients who received first-line platinum-pemetrexed chemotherapy in combination with pembrolizumab. We evaluated OS and PFS using Kaplan-Meier curves and multivariate Cox regression.

Results: Among patients treated with platinum-pemetrexed-pembrolizumab, TTF-1-negative patients showed significantly shorter OS and numerically shorter PFS compared to TTF-1-positive patients. Median OS was 13 months for TTF-1-negative patients and 21 months for TTF-1-positive patients (P=0.01). Median PFS was 10 vs. 13 months, respectively (P=0.11). In the overall cohort, TTF-1 negativity was independently associated with a 2.3-fold increased risk of mortality (hazard ratio =2.288, 95% confidence interval: 1.073-4.879, P=0.03).

Conclusions: TTF-1 negativity is an independent adverse prognostic factor in patients with stage IV lung adenocarcinoma and low PD-L1 expression. The observed differences in survival suggest that platinum-pemetrexed-pembrolizumab may be less effective for TTF-1-negative patients, and that alternative strategies should be explored in this high-risk subgroup.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
7.20
自引率
2.50%
发文量
137
期刊介绍: Translational Lung Cancer Research(TLCR, Transl Lung Cancer Res, Print ISSN 2218-6751; Online ISSN 2226-4477) is an international, peer-reviewed, open-access journal, which was founded in March 2012. TLCR is indexed by PubMed/PubMed Central and the Chemical Abstracts Service (CAS) Databases. It is published quarterly the first year, and published bimonthly since February 2013. It provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer. Specific areas of its interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信